| 000 | 01069 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250512202514.0 | ||
| 264 | 0 | _c19820708 | |
| 008 | 198207s 0 0 eng d | ||
| 022 | _a0012-6578 | ||
| 024 | 7 |
_a10.1177/106002808201600203 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPolk, R E | |
| 245 | 0 | 0 |
_aNew drug evaluations: moxalactam (Moxam, Eli Lilly). _h[electronic resource] |
| 260 |
_bDrug intelligence & clinical pharmacy _cFeb 1982 |
||
| 300 |
_a104-12 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xmetabolism |
| 650 | 0 | 4 |
_aBacteria _xdrug effects |
| 650 | 0 | 4 |
_aBacterial Infections _xdrug therapy |
| 650 | 0 | 4 |
_aCephalosporins _xtherapeutic use |
| 650 | 0 | 4 |
_aCephamycins _xmetabolism |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKinetics |
| 650 | 0 | 4 | _aMoxalactam |
| 773 | 0 |
_tDrug intelligence & clinical pharmacy _gvol. 16 _gno. 2 _gp. 104-12 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/106002808201600203 _zAvailable from publisher's website |
| 999 |
_c6210561 _d6210561 |
||